No Yes Ok

LSP Invests in $100 M Series C of HotSpot Therapeutics



to Advance First-in-Class Allosteric Drug Discovery Platform to the Clinic

 

Financing will accelerate HotSpot's transition into a clinical development company while enabling expansion of itrs product pipeline

 

Boston, Mass., Nov 30, 2021 - LSP, one of the leading life sciences and health care investors, today announced its investment in HotSpot Therapeutics, a private pharmaceutical company pioneering first-in-class allosteric therapies for oncology and immunology patients targeting regulatory sites on proteins referred to as “natural hotspots”. The funding is part of the $100 million Series C financing led by Pivotal bioventures with participation of B capital, Monashee Investment Management, CaaS Capital Management, Revelation Partners and Pavilion Capital and inside investors. In conjunction with this financing, Fouad Azzam, PhD, General Partner at LSP will join the HotSpot Board of Directors. LSP is investing from its LSP 7 fund.

 

The new financing will be used to continue advancing HotSpot’s Smart AllosteryTM platform focused on undrugged and poorly druggable targets, and the company’s existing pipeline. “With the support of top-tier healthcare and technology investors, we can expand on the significant productivity of the Smart Allostery™ platform to enable a treasure trove of sought after targets and thereby develop medicines that benefit patients,” said Jonathan Montagu, Co-Founder and Chief Executive Officer of HotSpot Therapeutics. “We have diligently established a deep pipeline of product opportunities in cancer and autoimmune disease, each offering a clear path to clinical value through precision and patient-targeted trial design.”

 

HotSpot’s Smart Allostery™ platform unlocks a vast range of disease-relevant proteins for the first time through the identification of protein pockets called “natural hotspots.” Natural hotspots are pockets that are decisive in protein function yet previously unexploited using conventional allostery approaches. The Smart Allostery™ platform encompasses a broad suite of AI-enabled technologies and the industry’s largest and most diverse chemical library tailored to hotspots.

 

Earlier this month, HotSpot announced new data validating its Smart Allostery™ platform in the elucidation and preclinical evaluation of a novel allosteric inhibitor of the E3 ubiquitin ligase CBL-B, an important target in cancer immunotherapy. The data show that HotSpot can successfully target CBL-B with the first and only selective small molecule inhibitors. Identified via its Smart Allostery™ platform, these small molecules promote T cell responses in vitro and in mice. Through allosteric inhibition of this negative regulator of immune cells, HotSpot’s small molecule CBL-B inhibitors offer the potential for increased immunotherapy efficacy for cancer patient populations that have historically exhibited poor treatment responses.

 

About HotSpot Therapeutics
HotSpot Therapeutics is targeting naturally occurring pockets on proteins called “natural hotspots” that are decisive in the control of cellular protein function. Largely unexploited by industry, these pockets are highly attractive for drug discovery and enable the systematic design of highly potent and selective small molecules that exhibit novel pharmacology. The company’s Smart Allostery™ technology platform utilizes AI-driven data mining of large and highly diverse data sets to identify pockets that matter on proteins, integrated with a tailored pharmacology toolkit and bespoke chemistry to rapidly deliver superior hotspot targeted small molecules. The company has successfully exploited natural hotspots across multiple classes including E3 ligases, kinases, and transcription factors. HotSpot has established a product pipeline of first-in-class small molecules for the treatment of cancer and autoimmune diseases each enabled by precision and patient-targeted clinical design. To learn more, visit www.hotspotthera.com.
 
 
About LSP
LSP is a European investment firm providing financing for life sciences and health care companies. LSP’s management has raised over $3.5 billion (€3 billion) and supported the growth of 150 companies since it started to invest in 1988, including signature deals such as argenx, Crucell and Neuravi. With offices in Amsterdam, Munich and Boston, LSP currently has the possibility to invest through five strategies, each having a distinctive investment scope and a dedicated team: LSP 7 invests in private early- to late-stage drug development and medical technology companies; LSP HEF 2 focuses on private late-stage medical technology companies; the LSP Dementia Fund invests in companies targeting neurodegenerative diseases; LSP Public targets public healthcare companies; and EBAC is LSP’s SPAC exclusively focussing on European biotech. LSP is an active contributor to the global life sciences industry and the European life science eco-system by assuming roles as initiators, founders and board members in various private and public bodies and organizations, for example being founder and board member of the Oncode Institute. For more information: lspvc.com. 

 

For more information please contact:

Fouad Azzam, General Manager at LSP

snmmnz@yfcip.pbz

« back to overview

go to archive back to news overview
Follow us

No Yes Ok

LSP Invests in $100 M Series C of HotSpot Therapeutics



to Advance First-in-Class Allosteric Drug Discovery Platform to the Clinic

 

Financing will accelerate HotSpot's transition into a clinical development company while enabling expansion of itrs product pipeline

 

Boston, Mass., Nov 30, 2021 - LSP, one of the leading life sciences and health care investors, today announced its investment in HotSpot Therapeutics, a private pharmaceutical company pioneering first-in-class allosteric therapies for oncology and immunology patients targeting regulatory sites on proteins referred to as “natural hotspots”. The funding is part of the $100 million Series C financing led by Pivotal bioventures with participation of B capital, Monashee Investment Management, CaaS Capital Management, Revelation Partners and Pavilion Capital and inside investors. In conjunction with this financing, Fouad Azzam, PhD, General Partner at LSP will join the HotSpot Board of Directors. LSP is investing from its LSP 7 fund.

 

The new financing will be used to continue advancing HotSpot’s Smart AllosteryTM platform focused on undrugged and poorly druggable targets, and the company’s existing pipeline. “With the support of top-tier healthcare and technology investors, we can expand on the significant productivity of the Smart Allostery™ platform to enable a treasure trove of sought after targets and thereby develop medicines that benefit patients,” said Jonathan Montagu, Co-Founder and Chief Executive Officer of HotSpot Therapeutics. “We have diligently established a deep pipeline of product opportunities in cancer and autoimmune disease, each offering a clear path to clinical value through precision and patient-targeted trial design.”

 

HotSpot’s Smart Allostery™ platform unlocks a vast range of disease-relevant proteins for the first time through the identification of protein pockets called “natural hotspots.” Natural hotspots are pockets that are decisive in protein function yet previously unexploited using conventional allostery approaches. The Smart Allostery™ platform encompasses a broad suite of AI-enabled technologies and the industry’s largest and most diverse chemical library tailored to hotspots.

 

Earlier this month, HotSpot announced new data validating its Smart Allostery™ platform in the elucidation and preclinical evaluation of a novel allosteric inhibitor of the E3 ubiquitin ligase CBL-B, an important target in cancer immunotherapy. The data show that HotSpot can successfully target CBL-B with the first and only selective small molecule inhibitors. Identified via its Smart Allostery™ platform, these small molecules promote T cell responses in vitro and in mice. Through allosteric inhibition of this negative regulator of immune cells, HotSpot’s small molecule CBL-B inhibitors offer the potential for increased immunotherapy efficacy for cancer patient populations that have historically exhibited poor treatment responses.

 

About HotSpot Therapeutics
HotSpot Therapeutics is targeting naturally occurring pockets on proteins called “natural hotspots” that are decisive in the control of cellular protein function. Largely unexploited by industry, these pockets are highly attractive for drug discovery and enable the systematic design of highly potent and selective small molecules that exhibit novel pharmacology. The company’s Smart Allostery™ technology platform utilizes AI-driven data mining of large and highly diverse data sets to identify pockets that matter on proteins, integrated with a tailored pharmacology toolkit and bespoke chemistry to rapidly deliver superior hotspot targeted small molecules. The company has successfully exploited natural hotspots across multiple classes including E3 ligases, kinases, and transcription factors. HotSpot has established a product pipeline of first-in-class small molecules for the treatment of cancer and autoimmune diseases each enabled by precision and patient-targeted clinical design. To learn more, visit www.hotspotthera.com.
 
 
About LSP
LSP is a European investment firm providing financing for life sciences and health care companies. LSP’s management has raised over $3.5 billion (€3 billion) and supported the growth of 150 companies since it started to invest in 1988, including signature deals such as argenx, Crucell and Neuravi. With offices in Amsterdam, Munich and Boston, LSP currently has the possibility to invest through five strategies, each having a distinctive investment scope and a dedicated team: LSP 7 invests in private early- to late-stage drug development and medical technology companies; LSP HEF 2 focuses on private late-stage medical technology companies; the LSP Dementia Fund invests in companies targeting neurodegenerative diseases; LSP Public targets public healthcare companies; and EBAC is LSP’s SPAC exclusively focussing on European biotech. LSP is an active contributor to the global life sciences industry and the European life science eco-system by assuming roles as initiators, founders and board members in various private and public bodies and organizations, for example being founder and board member of the Oncode Institute. For more information: lspvc.com. 

 

For more information please contact:

Fouad Azzam, General Manager at LSP

snmmnz@yfcip.pbz

« back to overview

go to archive back to newsoverview
X

MONTHLY REPORTS

Here you can subscribe for the monthly report of the LSP Life Sciences Fund